Breaking News Instant updates and real-time market news.

ABT

Abbott

$40.58

-0.2059 (-0.50%)

, ALR

Alere

$42.61

-0.55 (-1.27%)

15:25
10/17/16
10/17
15:25
10/17/16
15:25

Abbott, Alere preparing for trial, CTFN says

Even as Abbott (ABT) and Alere (ALR) continue to work with a court ordered mediator over their disagreements regarding their merger agreement, the two companies are preparing for a trial, says CTFN. Reference Link

ABT

Abbott

$40.58

-0.2059 (-0.50%)

ALR

Alere

$42.61

-0.55 (-1.27%)

  • 19

    Oct

  • 06

    Nov

ABT Abbott
$40.58

-0.2059 (-0.50%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ALR Alere
$42.61

-0.55 (-1.27%)

08/09/16
08/09/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 2. Chevron (CVX) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company offers "impressive financial resilience and dividend sustainability." 2. Alere (ALR) upgraded to Buy from Neutral at BTIG with analyst Dane Leone saying the 10-K helped to alleviate concerns that material deficiencies exist with the current financial model and is more comfortable with forecasts, and with the $56 price stated within the Abbott (ABT) merger agreement. 3. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Credit Suisse with analyst Jason West saying the presence of activist investor Marcato could provide a "floor" for the stock and a be a win-win for shareholders. 4. Waste Management (WM) upgraded to Overweight from Sector Weight at KeyBanc with analyst Joe Box saying he believes volumes are undergoing a positive inflection point and that the company's price gains are sustainable. 5. Skyworks (SWKS) upgraded to Outperform from Underperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/16
PIPR
08/24/16
NO CHANGE
PIPR
Abbott, Alere likely to agree to reduced takeover price, says Piper Jaffray
Piper Jaffray analyst Alex Olvera believes that Abbott (ABT) is building evidence to bolster its case that Alere (ALR) has undergone a material adverse change since Abbott agreed to acquire it. However, the analyst says he thinks that Delaware, where any litigation between the companies would occur, has never ruled that a material adverse change has occurred in any other case. Consequently, Olvera says there is "a high probability" that the takeover price for Alere will be lowered by 10%-15%. There is a "medium probability" that the cash component of the offer will be reduced and replaced with stock or Contingent Value Rights, according to the analyst. Finally, there is a "low probability" of the merger being terminated, he wrote.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.

TODAY'S FREE FLY STORIES

ALNY

Alnylam

$85.21

1.25 (1.49%)

06:26
06/26/17
06/26
06:26
06/26/17
06:26
Conference/Events
Alnylam to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 06

    Jul

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

06:25
06/26/17
06/26
06:25
06/26/17
06:25
Periodicals
Nest's head of industrial design is leaving to join LVMH, Recode reports »

Rocky Jacob, head of…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LVMUY

LVMH

$51.86

0.24 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

VC

Visteon

$95.91

1.05 (1.11%)

06:23
06/26/17
06/26
06:23
06/26/17
06:23
Upgrade
Visteon rating change  »

Visteon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$71.21

0.95 (1.35%)

06:22
06/26/17
06/26
06:22
06/26/17
06:22
Periodicals
Microsoft Windows 10 source code leaked, The Register reports »

Microsoft suffered a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 20

    Jul

ENG

ENGlobal

$1.19

0.1 (9.17%)

06:21
06/26/17
06/26
06:21
06/26/17
06:21
Hot Stocks
ENGlobal announces strategic alliance with Coggins International »

ENGlobal Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$32.76

0.46 (1.42%)

06:18
06/26/17
06/26
06:18
06/26/17
06:18
Hot Stocks
Genentech: Emicizumab showed reduction in bleeds across two pivotal studies »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Jul

  • 30

    Jul

GM

General Motors

$34.20

0.01 (0.03%)

06:17
06/26/17
06/26
06:17
06/26/17
06:17
Periodicals
General Motors settles hundreds of ignition switch lawsuits, Reuters reports »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ILMN

Illumina

$185.28

2.29 (1.25%)

06:16
06/26/17
06/26
06:16
06/26/17
06:16
Hot Stocks
Genomics England adopts Illumina's BaseSpace variant interpreter for cancer »

Illumina and Genomics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.88

-0.04 (-0.15%)

06:15
06/26/17
06/26
06:15
06/26/17
06:15
Hot Stocks
Taked, Biological E. Limited to develop low-cost combination vaccines »

Takeda Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

, VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

06:14
06/26/17
06/26
06:14
06/26/17
06:14
Periodicals
Harley-Davidson 'seriously considering bid' for Volkswagen's Ducati, WSJ says »

Harley-Davidson (HOG) is…

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

AUDVF

Audi AG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Oct

MMSI

Merit Medical

$37.80

0.7 (1.89%)

06:13
06/26/17
06/26
06:13
06/26/17
06:13
Recommendations
Merit Medical analyst commentary  »

Piper continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

SSNLF

Samsung

, QCOM

Qualcomm

$56.91

0.44 (0.78%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Periodicals
Samsung to launch Galaxy Note8 in late September, VentureBeat says »

Samsung (SSNLF) is…

SSNLF

Samsung

QCOM

Qualcomm

$56.91

0.44 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ALNY

Alnylam

$85.21

1.25 (1.49%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Hot Stocks
Alnylam: Givosian demonstrated decreased annual attack rate in study »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

CS

Credit Suisse

$13.74

-0.07 (-0.51%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Initiation
Credit Suisse initiated  »

Credit Suisse resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

IBM

IBM

$154.11

-0.29 (-0.19%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Hot Stocks
IBM, AEON to build blockchain-based financial platform for Asian market »

AEON Financial Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

UBS

UBS

$16.06

-0.08 (-0.50%)

06:08
06/26/17
06/26
06:08
06/26/17
06:08
Upgrade
UBS rating change  »

UBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MTNB

Matinas BioPharma

$2.77

0.25 (9.92%)

06:07
06/26/17
06/26
06:07
06/26/17
06:07
Hot Stocks
Matinas: Clinical, mycological responses for MAT2203 didn't meet expectations »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$8.28

0.48 (6.15%)

06:06
06/26/17
06/26
06:06
06/26/17
06:06
Periodicals
Pandora CEO Westergren planning to step down, Recode reports »

Tim Westergren, the CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BBY

Best Buy

$55.18

-0.04 (-0.07%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

06:04
06/26/17
06/26
06:04
06/26/17
06:04
Recommendations
Best Buy, Amazon.com analyst commentary  »

Piper views Best Buy as…

BBY

Best Buy

$55.18

-0.04 (-0.07%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Aug

LOW

Lowe's

$76.07

-2.27 (-2.90%)

06:02
06/26/17
06/26
06:02
06/26/17
06:02
Hot Stocks
Lowe's completes $512M acquisition of Maintenance Supply Headquarters »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMID

American Midstream Partners

$11.95

0.25 (2.14%)

06:01
06/26/17
06/26
06:01
06/26/17
06:01
Hot Stocks
American Midstream Partners announces binding open season for Bakken System »

American Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACTG

Acacia Research

$4.10

0.05 (1.23%)

06:00
06/26/17
06/26
06:00
06/26/17
06:00
Hot Stocks
Acacia Research enters into patent license agreement with ZTE Corporation »

Acacia Research announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:00
06/26/17
06/26
06:00
06/26/17
06:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.74

0.38 (1.70%)

05:58
06/26/17
06/26
05:58
06/26/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$119.43

0.51 (0.43%)

05:58
06/26/17
06/26
05:58
06/26/17
05:58
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.